ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2643

Comparative Study of Renal Transplantation Due to Rapidly Progressive Glomerulonephritis (RPGN): Study of 42 Patients from a Single Tertiary Centre

Lara Sanchez-Bilbao1, Marina De Cos-Gomez 2, Iñigo Gonzalez-Mazon 3, Belén Atienza-Mateo 1, Jose Luis Martín-Varillas 1, Mónica Calderón-Goercke 4, DIANA PRIETO- PENA 3, Juan Carlos Ruiz-San Millan 2, Miguel A Gonzalez-Gay 1 and Ricardo Blanco 1, 1Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain, 2Nephrology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, 3Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, 4Hospital Marqués de Valdecilla, Santander, Cantabria, Spain

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: ANCA

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: Vasculitis – ANCA-Associated Poster I

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Rapidly Progressive Glomerulonephritis (RPGN) is characterized clinically by a rapid and severe decline in kidney function. Thus, this entity may lead to an end stage renal disease, with kidney transplantation. RPGN is classificated in three groups: a) Type I or associated to anti-glomerular basement membrane antibodies (RPGN-GBMa), b) Type II or associated to immunocomplexes (RGPN-immunocomplexes), and c) Type III or pauci-immune (RPGN-pauci-immune). Besides, RPGN can be primary, without extra-renal involvement (RPGN-renal-limited), or secondary to systemic autoimmune disorders (RPGN-SAD), infectious diseases or drugs. Kidney transplantation in RPGN-SAD may be associated to a worse outcome.

In a series of 42 patients with first transplantation due to RPGN our aim was to assess a) clinical features of the three types of RPGN, b) comparison of post-transplant survival and graft survival between these three types.

Methods: We study three groups of patients according to renal biopsy: a) RPGN-GBMa (n = 11), b) RPGN-immunocomplexes (n = 2) and c) RPGN-pauci-immune (n=29).

All these patients were transplanted in a single reference University Hospital. The main outcome variables were a) graft survival up to 15 years and patient survival up to 30 years and b) evolution of renal function (serum creatinine and proteinuria) in the first 5 years of follow-up. Cumulative survival rates after transplantation were estimated by the Kaplan-Meier method and compared between groups using the log-rank test. Kruskal-Wallis test was used to compare quantitative variables and chi2/Fisher’s exact test for qualitative variables.

Results: We included a total of 42 patients with renal transplant due to RPGN, with a mean age at diagnosis of 44.87±17.01 years (48.53±17.45 at the time of the transplant). No significant differences at baseline were observed between the three RPGN groups regarding sex, age and cardiovascular risk factors. Renal biopsy had been performed in the 42 patients with RPGN: type I or RPGN-GBMa (n=11, 26.2%), type II or RPGN-immunocomplexes (n=2, 4.8%) and type III or RPGN-pauci-immune (n=29, 69.0%).

It was also reported the presence or absence of systemic autoimmune disorders (31% RPGN-SAD and 69% RPGN-renal-limited). According to the presentation and the clinical characteristics of the patients, another classification has been established: a) type I (18.2% (2) Goodpasture-syndrome), b) type II (100% renal-limited), c) type III (13.8% (4) granulomatosis with polyangiitis and 20.70% (6) microscopic polyangiitis. The evolution of serum creatinine and the proteinuria after the transplant is shown in TABLE 1. There were no significant differences between the three groups in the serum creatinine values during at 1st, 6th, 12th, 36th and 60th months post-transplant. Neither differences were found in terms of graft and patient survival between the 3 groups (Figures 1 and 2).

Conclusion: Our study shows similar graft and patient survival as well as renal outcome in renal transplant due to the three types of RPGN. Therefore, renal transplantation could be the best option for patients with end stage renal disease due to RPGN regardless of systemic manifestations.


Disclosure: L. Sanchez-Bilbao, None; M. De Cos-Gomez, None; I. Gonzalez-Mazon, None; B. Atienza-Mateo, None; J. Martín-Varillas, None; M. Calderón-Goercke, None; D. PRIETO- PENA, None; J. Ruiz-San Millan, None; M. Gonzalez-Gay, Abbvie, 2, 5, 8, Celgene, 5, 8, Janssen, 2, MSD, 2, 5, 8, Pfizer, 5, 8, Roche, 2, 5, 8, Sanofi, 5, 8, Sobi, 5, 8; R. Blanco, None.

To cite this abstract in AMA style:

Sanchez-Bilbao L, De Cos-Gomez M, Gonzalez-Mazon I, Atienza-Mateo B, Martín-Varillas J, Calderón-Goercke M, PRIETO- PENA D, Ruiz-San Millan J, Gonzalez-Gay M, Blanco R. Comparative Study of Renal Transplantation Due to Rapidly Progressive Glomerulonephritis (RPGN): Study of 42 Patients from a Single Tertiary Centre [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/comparative-study-of-renal-transplantation-due-to-rapidly-progressive-glomerulonephritis-rpgn-study-of-42-patients-from-a-single-tertiary-centre/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparative-study-of-renal-transplantation-due-to-rapidly-progressive-glomerulonephritis-rpgn-study-of-42-patients-from-a-single-tertiary-centre/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology